Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.

A second isoform of the human vesicular monoamine transporter (hVMAT) has been cloned from a pheochromocytoma cDNA library. The contribution of the two transporter isoforms to monoamine storage in human neuroendocrine tissues was examined with isoform-specific polyclonal antibodies against hVMAT1 and hVMAT2. Central, peripheral, and enteric neurons express only VMAT2. VMAT1 is expressed exclusively in neuroendocrine, including chromaffin and enterochromaffin, cells. VMAT1 and VMAT2 are coexpressed in all chromaffin cells of the adrenal medulla. VMAT2 alone is expressed in histamine-storing enterochromaffin-like cells of the oxyntic mucosa of the stomach. The transport characteristics and pharmacology of each VMAT isoform have been directly compared after expression in digitonin-permeabilized fibroblastic (CV-1) cells, providing information about substrate feature recognition by each transporter and the role of vesicular monoamine storage in the mechanism of action of psychopharmacologic and neurotoxic agents in human. Serotonin has a similar affinity for both transporters. Catecholamines exhibit a 3-fold higher affinity, and histamine exhibits a 30-fold higher affinity, for VMAT2. Reserpine and ketanserin are slightly more potent inhibitors of VMAT2-mediated transport than of VMAT1-mediated transport, whereas tetrabenazine binds to and inhibits only VMAT2. N-methyl-4-phenylpyridinium, phenylethylamine, amphetamine, and methylenedioxymethamphetamine are all more potent inhibitors of VMAT2 than of VMAT1, whereas fenfluramine is a more potent inhibitor of VMAT1-mediated monamine transport than of VMAT2-mediated monoamine transport. The unique distributions of hVMAT1 and hVMAT2 provide new markers for multiple neuroendocrine lineages, and examination of their transport properties provides mechanistic insights into the pharmacology and physiology of amine storage in cardiovascular, endocrine, and central nervous system function.

Policy Development at a Local Level to Mitigate Depositing Endocrine Disruptors into Aquatic Ecosystems

Endocrine disruptors are suspected to cause disruption to organisms in aquatic environments. Intersex fish and skewed populations of females outnumbering males have been found where effluents from municipal wastewater treatment plants enter into receiving waters. The science needed to substantiate a link of these suspected pollutants as the cause of problems to human health or the environmental is in its infancy. Empirical research was used to identify suspected endocrine disruptors, their sources, and the difficulties involved in regulating these emerging contaminants. This project examined entities that are addressing endocrine disruption and provides cost-effective recommendations for municipalities to develop policies to mitigate the amount of endocrine disruptors entering into receiving waters and limiting the effects caused by endocrine disruption.

Removal of endocrine disrupting compounds from wastewater: a comparison between a conventional activated sludge with tertiary treatment and membrane bioreactors

Póster presentado en 19th International Congress of Chemical and Process Engineering, Prague, Czech Republic August 28th-September 1st, 2010.

TERT promoter mutations in pancreatic endocrine tumours are rare and mainly found in tumours from patients with hereditary syndromes

One of the hallmarks of cancer is its unlimited replicative potential that needs a compensatory mechanism for the consequential telomere erosion. Telomerase promoter (TERTp) mutations were recently reported as a novel mechanism for telomerase re-activation/expression in order to maintain telomere length. Pancreatic endocrine tumors (PETs) were so far recognized to rely mainly on the alternative lengthening of telomeres (ALT) mechanism. It was our objective to study if TERTp mutations were present in pancreatic endocrine tumors (PET) and could represent an alternative mechanism to ALT. TERTp mutations were detected in 7% of the cases studied and were mainly associated to patients harbouring hereditary syndromes. In vitro, using PET-derived cell lines and by luciferase reporter assay, these mutations confer a 2 to 4-fold increase in telomerase transcription activity. These novel alterations are able to recruit ETS transcription factor members, in particular GABP-α and ETV1, to the newly generated binding sites. We report for the first time TERTp mutations in PETs and PET-derived cell lines. Additionally, our data indicate that these mutations serve as an alternative mechanism and in an exclusive manner to ALT, in particular in patients with hereditary syndromes.

The United States Environmental Protection Agency announces the availability of 1996 grants for research on endocrine disruptors, role of interindividual variation in human susceptibility to cancer, risk-based decisions for contaminated sediments.

Mode of access: Internet.

Understanding multiple endocrine neoplasia type 1.

Mode of access: Internet.

Endocrine glands and the sympathetic system /

Mode of access: Internet.

The endocrine organs; an introduction to the study of internal secretion.

"Founded upon a course of lectures (Lane Medical Lectures) delivered at Stanford University, California, in the summer of 1913."

Endocrine therapy in general practice,

"Published in response to requests for the printing of a series f lectures given before a variety of medical organizations during the last two years."--Pref.

Endocrine therapy in general practice,

"References for further reading" at end of some of the chapters."

Endocrine therapy in general practice /

Includes bibliographical references and index.

Endocrine therapy in general practice,

"References for further reading" at end of some of the chapters."

Current cancer research on endocrine neoplasms : epidemiology, etiology and related biology.

Prepared for the ICRDB Program by the Current Cancer Research Project Analysis Center.

An endocrine handbook,

Mode of access: Internet.

Urea based osmoregulation and endocrine control in elasmobranch fish with special reference to euryhalinity

Since the landmark contributions of Homer Smith and co-workers in the 1930s there has been a considerable advance in our knowledge regarding the osmoregulatory strategy of elasmobranch fish. Smith recognised that urea was retained in the body fluids as part of the 'osmoregulatory ballast' of elasmobranch fish so that body fluid osmolality is raised to a level that is iso- or slightly hyper-osmotic to that of the surrounding medium. From studies at that time he also postulated that many marine dwelling elasmobranchs were not capable of adaptation to dilute environments. However, more recent investigations have demonstrated that, at least in some species, this may not be the case. Gradual acclimation of marine dwelling elasmobranchs to varying environmental salinities under laboratory conditions has demonstrated that these fish do have the capacity to acclimate to changes in salinity through independent regulation of Na+, Cl- and urea levels. This suggests that many of the presumed stenohaline marine elasmobranchs could in fact be described as partially euryhaline. The contributions of Thomas Thorson in the 1970s demonstrated the osmoregulatory strategy of a fully euryhaline elasmobranch, the bull shark, Carcharhinus leucas, and more recent investigations have examined the mechanisms behind this strategy in the euryhaline elasmobranch, Dasyatis sabina. Both partially euryhaline and fully euryhaline species utilise the same physiological processes to control urea, Na+ and Cl- levels within the body fluids. The role of the gills, kidney, liver, rectal gland and drinking process is discussed in relation to the endocrine control of urea, Na+ and Cl- levels as elasmobranchs acclimate to different environmental salinities. (C) 2003 Elsevier Inc. All rights reserved.